المؤلفون: Forss A; Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.; Gastroenterology Unit, Department of Gastroenterology, Dermatovenereology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden., Flis P; Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.; Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden., Sotoodeh A; Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden., Kapraali M; Gastroenterology Unit, Department of Gastroenterology, Dermatovenereology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden.; Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden., Rosenborg S; Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.; Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden.

المصدر: Scandinavian journal of gastroenterology [Scand J Gastroenterol] 2024 Jul; Vol. 59 (7), pp. 821-829. Date of Electronic Publication: 2024 Apr 29.

نوع المنشور: Systematic Review; Journal Article; Review

بيانات الدورية: Publisher: Informa Healthcare Country of Publication: England NLM ID: 0060105 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1502-7708 (Electronic) Linking ISSN: 00365521 NLM ISO Abbreviation: Scand J Gastroenterol Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal, Humanized*/adverse effects , Antibodies, Monoclonal, Humanized*/therapeutic use , Nephritis, Interstitial*/chemically induced , Gastrointestinal Agents*/adverse effects , Gastrointestinal Agents*/therapeutic use , Inflammatory Bowel Diseases*/drug therapy , Inflammatory Bowel Diseases*/complications, Humans ; Colitis, Ulcerative/drug therapy ; Acute Disease

المؤلفون: Huang Z; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China; Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China., Chen T; Department of Hepatobiliary Surgery, The Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China., Li W; Department of Biliopancreatic Surgery, Sun Yat-sen Memorial Hospital, Guangzhou, China., He W; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China; Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China., Liu S; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China; Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China., Wu Z; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China; Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China., Li B; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China; Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China., Yuan Y; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China; Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China., Qiu J; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China; Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China. Electronic address: qiujl@sysucc.org.cn.

المصدر: International immunopharmacology [Int Immunopharmacol] 2024 Sep 30; Vol. 139, pp. 112711. Date of Electronic Publication: 2024 Jul 18.

نوع المنشور: Journal Article; Multicenter Study

بيانات الدورية: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 100965259 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-1705 (Electronic) Linking ISSN: 15675769 NLM ISO Abbreviation: Int Immunopharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Hepatocellular*/therapy , Carcinoma, Hepatocellular*/mortality , Carcinoma, Hepatocellular*/drug therapy , Liver Neoplasms*/therapy , Liver Neoplasms*/drug therapy , Liver Neoplasms*/mortality , Bevacizumab*/administration & dosage , Bevacizumab*/therapeutic use , Chemoembolization, Therapeutic*/methods , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/administration & dosage , Infusions, Intra-Arterial*, Humans ; Male ; Female ; Middle Aged ; Aged ; Retrospective Studies ; Adult ; Tumor Burden ; Hepatic Artery ; Treatment Outcome ; Combined Modality Therapy ; Cohort Studies

المؤلفون: Merzel Šabović EK; Department of Dermatovenerology, University Medical Centre Ljubljana, Gradiškova ulica 10, Ljubljana, Slovenia. em2230@student.uni-lj.si.; Faculty of Medicine, University of Ljubljana, Vrazov trg 2, Ljubljana, Slovenia. em2230@student.uni-lj.si., Kraner Šumenjak T; Faculty of Agriculture and Life Sciences, University of Maribor, Pivola 10, Hoče, Slovenia., Janić M; Faculty of Medicine, University of Ljubljana, Vrazov trg 2, Ljubljana, Slovenia.; Clinical Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Zaloška 7, Ljubljana, Slovenia.

المصدر: Archives of dermatological research [Arch Dermatol Res] 2024 Sep 27; Vol. 316 (9), pp. 647. Date of Electronic Publication: 2024 Sep 27.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8000462 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-069X (Electronic) Linking ISSN: 03403696 NLM ISO Abbreviation: Arch Dermatol Res Subsets: MEDLINE

مواضيع طبية MeSH: Psoriasis*/drug therapy , Psoriasis*/diagnosis , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/administration & dosage , Adalimumab*/therapeutic use , Adalimumab*/administration & dosage , Methotrexate*/therapeutic use , Methotrexate*/administration & dosage , Biological Products*/therapeutic use , Biological Products*/administration & dosage, Humans ; Male ; Female ; Adult ; Cross-Sectional Studies ; Middle Aged ; Dermatologic Agents/therapeutic use ; Dermatologic Agents/administration & dosage ; Treatment Outcome ; Metabolic Diseases/drug therapy

المؤلفون: Zhang Y; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Huang Y; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Yang Y; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Zhao Y; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Zhou T; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Chen G; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Zhao S; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Zhou H; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Ma Y; Department of Clinical Research, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Hong S; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Zhao H; Department of Clinical Research, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Zhang L; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. zhangli@sysucc.org.cn., Fang W; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. fangwf@sysucc.org.cn.

المصدر: Signal transduction and targeted therapy [Signal Transduct Target Ther] 2024 Sep 27; Vol. 9 (1), pp. 255. Date of Electronic Publication: 2024 Sep 27.

نوع المنشور: Journal Article; Clinical Trial, Phase II; Clinical Trial, Phase I; Multicenter Study

بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101676423 Publication Model: Electronic Cited Medium: Internet ISSN: 2059-3635 (Electronic) Linking ISSN: 20593635 NLM ISO Abbreviation: Signal Transduct Target Ther Subsets: MEDLINE

مواضيع طبية MeSH: Cisplatin*/administration & dosage , Cisplatin*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Etoposide*/administration & dosage , Etoposide*/adverse effects , Small Cell Lung Carcinoma*/drug therapy , Small Cell Lung Carcinoma*/pathology , Lung Neoplasms*/drug therapy , Lung Neoplasms*/pathology , Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/therapeutic use, Humans ; Male ; Middle Aged ; Female ; Aged ; Adult

المؤلفون: Göbel H; Schmerzklinik Kiel, Migräne und Kopfschmerzzentrum, Kiel, Deutschland. hg@schmerzklinik.de., Schlegel E; Zentrum für Neurologisch-Psychiatrische Studien, ZNS GmbH, Siegen, Deutschland., Jaeger K; Novartis Pharma GmbH, Nürnberg, Deutschland., Ortler S; Novartis Pharma GmbH, Nürnberg, Deutschland., Leist L; Novartis Pharma GmbH, Nürnberg, Deutschland.

المصدر: The journal of headache and pain [J Headache Pain] 2024 Sep 25; Vol. 25 (1), pp. 157. Date of Electronic Publication: 2024 Sep 25.

نوع المنشور: Journal Article; Multicenter Study

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100940562 Publication Model: Electronic Cited Medium: Internet ISSN: 1129-2377 (Electronic) Linking ISSN: 11292369 NLM ISO Abbreviation: J Headache Pain Subsets: MEDLINE

مواضيع طبية MeSH: Migraine Disorders*/drug therapy , Migraine Disorders*/prevention & control , Antibodies, Monoclonal, Humanized*/adverse effects , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/administration & dosage, Humans ; Female ; Male ; Adult ; Middle Aged ; Calcitonin Gene-Related Peptide Receptor Antagonists/adverse effects ; Calcitonin Gene-Related Peptide Receptor Antagonists/administration & dosage ; Calcitonin Gene-Related Peptide Receptor Antagonists/therapeutic use ; Treatment Outcome

المؤلفون: Husni ME; Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, Ohio, USA husnie@ccf.org.; Orthopedic and Rheumatologic Institute, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA., Mease PJ; Swedish Medical Center and Providence St. Joseph Health/University of Washington, Seattle, Washington, USA., Merola JF; Department of Dermatology, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Division of Rheumatology, Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA., Tillett W; Royal National Hospital for Rheumatic Diseases, Bath, UK.; Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, UK., Goldammer N; UCB, Monheim am Rhein, Germany., Ink B; UCB, Slough, UK., Coarse J; UCB, Morrisville, North Carolina, USA., Lambert J; UCB, Colombes, France., Taieb V; UCB, Colombes, France., Gladman DD; Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.

المصدر: RMD open [RMD Open] 2024 Sep 23; Vol. 10 (3). Date of Electronic Publication: 2024 Sep 23.

نوع المنشور: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial

بيانات الدورية: Publisher: BMJ Publishing Group Country of Publication: England NLM ID: 101662038 Publication Model: Electronic Cited Medium: Internet ISSN: 2056-5933 (Electronic) Linking ISSN: 20565933 NLM ISO Abbreviation: RMD Open Subsets: MEDLINE

مواضيع طبية MeSH: Quality of Life* , Patient Reported Outcome Measures* , Arthritis, Psoriatic*/drug therapy , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/administration & dosage, Humans ; Male ; Female ; Middle Aged ; Treatment Outcome ; Double-Blind Method ; Adult ; Antirheumatic Agents/therapeutic use ; Antirheumatic Agents/administration & dosage ; Severity of Illness Index ; Adalimumab/therapeutic use ; Adalimumab/administration & dosage ; Fatigue/etiology

المؤلفون: Boonyaratanakornkit J; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center.; Department of Medicine, University of Washington, Seattle., Wang Q; GlaxoSmithKline, Stevenage, United Kingdom., Nader A; GlaxoSmithKline, Collegeville, Pennsylvania., Kimball L; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center., Stevens-Ayers T; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center., Levkova M; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center., Blazevic R; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center., Nguyen J; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center., Wright J; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center., Castor J; Department of Laboratory Medicine and Pathology, University of Washington., Greninger AL; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center.; Department of Laboratory Medicine and Pathology, University of Washington., Ford E; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center.; Department of Medicine, University of Washington, Seattle., Mielcarek M; Department of Medicine, University of Washington, Seattle.; Clinical Research Division, Fred Hutchinson Cancer Center., Fordred S; GlaxoSmithKline, Stevenage, United Kingdom., Han J; GlaxoSmithKline, Collegeville, Pennsylvania., Boeckh M; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center.; Department of Medicine, University of Washington, Seattle., Waghmare A; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center.; Infectious Diseases and Virology, Seattle Children's Hospital.; Department of Pediatrics, University of Washington, Seattle.

المصدر: The Journal of infectious diseases [J Infect Dis] 2024 Sep 23; Vol. 230 (3), pp. 670-679.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE

مواضيع طبية MeSH: Hematopoietic Stem Cell Transplantation*/adverse effects , Graft vs Host Disease*/drug therapy , Diarrhea*/drug therapy , Antibodies, Monoclonal, Humanized*/pharmacokinetics , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/administration & dosage, Humans ; Male ; Female ; Middle Aged ; Adult ; Aged ; SARS-CoV-2/immunology ; COVID-19 Drug Treatment ; Transplant Recipients ; COVID-19

المؤلفون: Paton NI; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.; Infectious Diseases Translational Research Programme, National University of Singapore, Singapore, Singapore.; Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom., Gurumurthy M; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Lu Q; Singapore Clinical Research Institute, Singapore, Singapore, Singapore., Leek F; Clinical Imaging Research Centre, National University of Singapore, Singapore, Singapore., Kwan P; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Koh HWL; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Molton J; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Mortera L; Quezon Institute, Quezon City, Philippines., Naval S; Lung Centre of the Philippines, Quezon City, Philippines., Bakar ZA; Institute of Respiratory Medicine, Kuala Lumpur, Malaysia., Pang YK; University of Malaya Medical Centre, Kuala Lumpur, Malaysia., Lum L; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Lim TK; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Cross GB; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Lekurwale G; Singapore Clinical Research Institute, Singapore, Singapore, Singapore., Choi H; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Au V; Institute of Cellular and Molecular Biology, Singapore, Singapore., Connolly J; Institute of Cellular and Molecular Biology, Singapore, Singapore., Hibberd M; Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.; Department of Microbiology, National University of Singapore, Singapore, Singapore., Green JA; GSK, Greenford, United Kingdom.

مؤلفون مشاركون: Pascolizumab Tuberculosis Trial Team

المصدر: The Journal of infectious diseases [J Infect Dis] 2024 Sep 23; Vol. 230 (3), pp. 590-597.

نوع المنشور: Journal Article; Randomized Controlled Trial

بيانات الدورية: Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE

مواضيع طبية MeSH: Tuberculosis, Pulmonary*/drug therapy , Rifampin*/administration & dosage , Rifampin*/therapeutic use , Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/adverse effects , Interleukin-4*, Humans ; Double-Blind Method ; Adult ; Female ; Male ; Middle Aged ; Antitubercular Agents/administration & dosage ; Antitubercular Agents/therapeutic use ; Antitubercular Agents/adverse effects ; Treatment Outcome ; Young Adult ; Proof of Concept Study ; Drug Therapy, Combination ; Dose-Response Relationship, Drug ; Placebos/administration & dosage

المؤلفون: Manna M; Department of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5A2, Canada.; Department of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada.; Saskatoon Cancer Centre, Saskatchewan Cancer Agency, Saskatoon, SK S7N 4H4, Canada., Brabant M; Department of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5A2, Canada., Greene R; Department of Biochemistry, Microbiology, and Immunology, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada., Chamberlain MD; Department of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada.; Saskatoon Cancer Centre, Saskatchewan Cancer Agency, Saskatoon, SK S7N 4H4, Canada., Kumar A; BC Cancer Surrey, University of British Columbia, Surrey, BC V3V 1Z2, Canada., Alimohamed N; Department of Medicine, University of Calgary, Calgary, AB T2N 4N2, Canada., Brezden-Masley C; Department of Oncology, University of Toronto, Toronto, ON M5S 1A1, Canada.

المصدر: Current oncology (Toronto, Ont.) [Curr Oncol] 2024 Sep 21; Vol. 31 (9), pp. 5694-5708. Date of Electronic Publication: 2024 Sep 21.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 9502503 Publication Model: Electronic Cited Medium: Internet ISSN: 1718-7729 (Electronic) Linking ISSN: 11980052 NLM ISO Abbreviation: Curr Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Triple Negative Breast Neoplasms*/drug therapy , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/pharmacology , Camptothecin*/analogs & derivatives , Camptothecin*/therapeutic use , Immunoconjugates*/therapeutic use, Humans ; Canada ; Female ; Neoplasm Metastasis ; Antineoplastic Agents/therapeutic use

المؤلفون: Shen C; Department of Geriatric Medicine & National Clinical Research Centre of Geriatric Disease, The Second Medical Center, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China.; Department of Interventional Radiology, Chinese PLA General Hospital, Beijing, 100853, China., Jiang W; Health Service Department of the Guard Bureau of the General Office of the Central Committee of the Communist Party of China, No. 15 Wenjin Street, Xicheng District, Beijing, 100017, China., Chen R; Department of Interventional Radiology, Chinese PLA General Hospital, Beijing, 100853, China., Li L; Department of Geriatric Medicine & National Clinical Research Centre of Geriatric Disease, The Second Medical Center, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China.; Department of Interventional Radiology, Chinese PLA General Hospital, Beijing, 100853, China., Wu Y; Health Service Department of the Guard Bureau of the General Office of the Central Committee of the Communist Party of China, No. 15 Wenjin Street, Xicheng District, Beijing, 100017, China., Tan L; Health Service Department of the Guard Bureau of the General Office of the Central Committee of the Communist Party of China, No. 15 Wenjin Street, Xicheng District, Beijing, 100017, China., Chen Y; Health Service Department of the Guard Bureau of the General Office of the Central Committee of the Communist Party of China, No. 15 Wenjin Street, Xicheng District, Beijing, 100017, China. chenyadongddd@outlook.com., Zhang W; Health Service Department of the Guard Bureau of the General Office of the Central Committee of the Communist Party of China, No. 15 Wenjin Street, Xicheng District, Beijing, 100017, China. zhangweiqiangmmwq@126.com., Wang Z; Department of Geriatric Medicine & National Clinical Research Centre of Geriatric Disease, The Second Medical Center, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China. zhijun_wangdr06@163.com.; Department of Interventional Radiology, Chinese PLA General Hospital, Beijing, 100853, China. zhijun_wangdr06@163.com.

المصدر: Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2024 Sep 20; Vol. 150 (9), pp. 427. Date of Electronic Publication: 2024 Sep 20.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7902060 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-1335 (Electronic) Linking ISSN: 01715216 NLM ISO Abbreviation: J Cancer Res Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Hepatocellular*/drug therapy , Carcinoma, Hepatocellular*/pathology , Carcinoma, Hepatocellular*/therapy , Liver Neoplasms*/drug therapy , Liver Neoplasms*/therapy , Liver Neoplasms*/pathology , Quinolines*/administration & dosage , Quinolines*/therapeutic use , Chemoembolization, Therapeutic*/methods , Phenylurea Compounds*/administration & dosage , Phenylurea Compounds*/therapeutic use , Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use, Humans ; Male ; Retrospective Studies ; Middle Aged ; Female ; Aged ; Adult